Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Locally Advanced Urothelial Carcinoma · Metastatic Urothelial Carcinoma · Solid Tumor · Urothelial Carcinoma · Solid Tumor, Adult · Bladder Cancer · Non-muscle-invasive Bladder Cancer · FGFR3 Gene Mutation · FGFR3 Gene Alteration · Advanced Solid Tumor · Advanced Urothelial Carcinoma · Urinary Tract Cancer · Urinary Tract Tumor · Urinary Tract Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 310 (planned)
- Started
- Nov 22, 2022
- Main results expected
- Nov 2026
- Fully finished
- Jun 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 Part A: To determine the maximum tolerated doses (MTD).
Measured over: Initiation of study treatment through 28 days.
Phase 1 Part B: To determine the recommended Phase 2 dose (R2PD).
Measured over: Initiation of study treatment through 28 days (up to approximately 18 months).
Phase 2: Overall Response Rate (ORR), defined by RECIST v1.1.
Measured over: Initiation of study treatment until disease progression, death, unacceptable toxicity, or withdrawal (up to 2 years).
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05544552 · record last updated 2026-01-12 · checked 2026-11-09 15:47 UTC